Kornimate/medical-research-clean huggingface dataset:
a nutrition-focused quality improvement program in hospitalized malnourished patients

Conditions: Malnutrition

Summary: this study includes pre and post-quality improvement program groups. a nutrition-focused quality improvement program will be implemented to assess the health and economic outcomes in malnourished hospitalized patients.


Eligibility criteria:
inclusion criteria: * subject is at risk / malnourished, defined by an mst score ≥ 2 the first 24 hours post hospital admission * patients are admitted for the following diagnoses: respiratory, digestive surgery, cardiology, general internal medicine (including endocrinology), and gastrointestinal * patient is able to consume foods and beverages orally * patients with life expectancy ≥ 30 days * patient is literate and willing to voluntarily sign and date informed consent form (icf) exclusion criteria: * subject has severe dementia or delirium and has no dedicated caregiver who could assure their compliance with qip study requirements * subject has an eating disorder, history of significant neurological or psychiatric disorder, or other conditions that may interfere with study product consumption or compliance with study protocol procedures * subject is known to be allergic or intolerant to any ingredient found in the study products * subject is pregnant * subject is intubated, receiving tube feeding or parenteral nutrition
paclitaxel/cisplatin/fluorouracil followed by paclitaxel/cisplatin/radiotherapy and esophagectomy for esophageal cancer

Conditions: Esophageal Cancer

Summary: we hypothesize that one-cycle induction chemotherapy may also help to identify chemo-responsive esophageal cancer patients who are highly treatable by definitive ccrt.

we hypothesize that one-cycle induction chemotherapy may also help to identify chemo-responsive esophageal cancer patients who are highly treatable by definitive ccrt.in order to test this hypothesis, we thus propose this phase ii clinical study to verify the role of "response to one-cycle induction chemotherapy"in the prediction of pathologic complete response rate to ccrt and tje outcomes for patients with loco-regional esophageal cancer.

Eligibility criteria:
inclusion criteria: * pathologically proven esophageal cancer * locally advanced diseases t3 n0-1 m0; t1-3 n1 m0; t1-3 or n0-1 m1a * age ≥ 18 years old * ecog ≤ 2 * creatinine \< 1.5 mg/dl ast, alt \< 2.5 x upper normal limits bilirubin \< 2.0 mg/dl * wbc \> 4,000/μl or anc\>2,000/μl * platelet \> 100,000//μl * informed consent exclusion criteria: * invasion to surrounding organs (t4 disease) * distant mets (except m1a) * prior thoracic irradiation * presence of other squamous cell carcinoma of aerodigestive way * symptomatic co-morbid diseases * previous malignancy

Keywords: esophageal cancer esophagectomy paclitaxel induction chemotherapy
fimasartan on hypertensive cardiac disease with left ventricular hypertrophy estimated by ecg

Conditions: Left Ventricular Hypertrophy; Hypertension

Summary: assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients

patients who were diagnosed with left ventricular hypertrophy (lvh) by ecg at the start of the study are followed up at 3-month intervals for 1 year. increase fimasartan if blood pressure is not controlled.

Eligibility criteria:
inclusion criteria: * patients who have been treated or not treated with hypertension from 20 to 80 years of age * patients with electrocardiographic left ventricular hypertrophy (in this study, we define left ventricular hypertrophy if one of the following two criteria is met) 1. ravl+sv3 \> 20mm(m). 16mm(f) 2. sv1+rv5 or rv6 \> 35mm. * patients who are taking or expecting fimasartan exclusion criteria: * patients with unstable angina or myocardial infarction within 3 months * patients with clinically significant severe valve disease, congenital heart disease, peripheral vascular disease, cerebrovascular disease * clinically significant severe congestive heart failure patients * patients with renal dialysis * clinically significant renal disease patients * patients with clinically significant hepatic impairment * patients with a history of alcohol or substance abuse * patients with hypersensitivity to angiotensin-receptor blocker * patients needing angiotensin-receptor blocker drugs other than fimasartan * for women, pregnancy, patients who are breastfeeding or planning to become pregnant * a person who is determined to be inappropriate by the investigator * patients participating in other clinical trials
the registry study on multimodality treatment for cerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: the registry study on multimodality treatment for cerebral hemorrhage (research) aims to address these challenges by establishing a comprehensive national registry. this initiative will collect detailed, longitudinal data on the clinical characteristics, treatment modalities, and outcomes of patients with ich across various regions. by leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the research registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.

cerebral hemorrhage, also known as intracerebral hemorrhage (ich), is a severe neurological condition characterized by abrupt bleeding within the brain tissues, leading to high rates of mortality and morbidity worldwide. in china, where the burden of cerebrovascular diseases is substantial due to the aging population and prevalence of risk factors such as hypertension and diabetes, the impact of ich is particularly pronounced. despite advancements in medical science, the prognosis for patients suffering from ich remains poor, with a high proportion of survivors experiencing significant disability. current treatment protocols for ich involve a range of strategies, from conservative management to surgical interventions. however, the heterogeneity in clinical practices and patient responses highlights a significant gap in standardized treatment efficacy. this registry study is not only pivotal for enhancing the understanding of effective treatment combinations but also crucial for identifying potential disparities in the application of treatment modalities across different healthcare settings. through the analytical power of this large-scale, multicentric data, research will contribute significantly to optimizing treatment paradigms and ultimately, shaping policy changes that aim to reduce the mortality and enhance the recovery rates of patients suffering from cerebral hemorrhage. there is an urgent need to evaluate these multimodal treatment approaches on a broader scale to understand their real-world effectiveness and develop guidelines that can be systematically applied to improve patient outcomes.

Eligibility criteria:
inclusion criteria: * cerebral hemorrhage exclusion criteria: -

Keywords: intracerebral hemorrhage outcome management surgical interventions real-world disparities multicentric data
interactive cancer communication system (iccs) directed physical activity enhancement for colon cancer survivors

Conditions: Colon Cancer

Summary: this study will develop and test the benefits of a new iccs (interactive cancer communication system), a mobile comprehensive health enhancement support system (survivorship chess) in colon cancer survivors. survivorship chess will provide information, tools, and a support system based on our previous work with fresh start and chess, two highly successful interventions that have promoted lifestyle change among cancer patients and survivors. survivorship chess will be designed to help subjects develop 1) competence in information gathering, decision-making, and behaviors they are trying to change, 2) social support systems to help deal with the cancer experience, and 3) autonomy that comes with regaining a sense of control over their lives; this in turn, will help them adopt or maintain healthy lifestyle behaviors and improve their quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of stage i-iii loco-regional colon cancer within the previous 12 months with no evidence of recurrence or new cancers. participants may be recruited at any time after the initial diagnosis (up to 12 months). baseline data collection will occur no earlier than 6 weeks after completion of adjuvant treatment * at least 21 years of age * able to speak and read english (educational attainment of at lease 6th grade) * engaged in physical activities less than 8 metabolic equivalent tasks (mets) per week * not homeless exclusion criteria: * pre-existing medical condition(s) that preclude adherence to an unsupervised exercise program which includes subjects with severe orthopedic conditions or scheduled for a hip or knee replacement within six months; paralysis; end-stage renal disease; dementia; as well as subjects who have unstable angina or who have experienced a heart attack; congestive heart failure or pulmonary conditions that require oxygen or hospitalization within six months; or uncorrected vision or hearing problems or other ergonomic conditions that would preclude the use of the smart phone.

Keywords: colon cancer patients who have completed treatment
photo-narrative study

Conditions: Child Development Disorder; Critical Illness; Neurologic Disorder

Summary: the objective of this study is to conduct a pilot randomized controlled trial (rct) of a photo-narrative communication intervention developed by our study team with patients/parents of children with severe neurological impairment (sni) and their pediatric intensive care unit (picu) clinicians to assess feasibility, acceptability, and early efficacy.


Eligibility criteria:
patients inclusion criteria: * ages 3 months-25 years * severe neurological impairment (including congenital/chromosomal, chronic central nervous system static or progressive conditions, or child \>6 months after severe traumatic brain injury * admitted to the pediatric icu at seattle children's and with medical team permission to approach * expected length of stay \>1 week * life expectancy \>4 weeks * previous discharge home parents inclusion criteria: * parent/legal guardian * english and/or spanish speaking (most common languages spoken at sch making up 95% of patients and families) * \>18 years of age clinicians inclusion criteria: * licensed physicians, fellows, residents, advanced practice nurse practitioners, nurses, or respiratory therapists * working in the pediatric icu at seattle children's hospital

Keywords: pediatric palliative care communication severe neurological impairment
assessment of efficacy of calprotectin and cross-linked n-telopeptides

Conditions: Peri-Implantitis; Dental Implant Failed

Summary: the study aims to assess the efficacy of calprotectin and cross-linked n-telopeptides of type i collagen levels in crevicular fluid as a biomarker in patients with peri-implantitis.

ethical approval will be obtained from the ethical committee of the riyadh elm university and written consent will be obtained from all the patients after explaining in detail the entire research protocol. inclusion criteria for the present study: * 10 patients who underwent dental implant procedure five to ten years ago; among these- 5 patients will be with healthy peri-implant status and 5 patients with presence of peri-implant diseases * patients of comparable age and gender distribution- patients within the age group of 25 to 45 years; and 3 males and 2 females in peri-implant diseases group and 3 males and 2 females in healthy peri-implant status group * patients with negative history of any systemic illness, metabolic disease. * patients with negative history of antibiotic therapy in past ninety days. after collecting the picf and gcf, examination of probing depth (pd), bleeding on probing (bop) and gingival index (gi) will be done.modified löe and silness criteria will be used for evaluating the gi score.using modification of criteria described by schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment. periodontal sites with pd of equal to or more than 3mm with gi score of equal to or more than 1mm and presence or absence of bop, will be categorized as peri-implant disease sites. periodontal sites with pd of less than 3mm with gi score of 0 and absence of bop will be categorized as healthy implant sites. sterile paper strips will be used for collecting picf samples, followed by picf sample preparation using modified criteria described previously in the literature. isolation of the picf sampling sites will be done using cotton roles. this will be followed by removal of supra-gingival plaques and gentle air drying. insertion of the periopaper will be done into the peri-implant crevice and will be kept there for thirty seconds. periotron will be used for measuring the volume of picf. further, all the samples will be sent to laboratory where elisa technique will be used for measuring the calprotectin

Eligibility criteria:
inclusion criteria: exclusion criteria: * patients with history of any systemic illness, metabolic disease. * patients with history of antibiotic therapy in past ninety days.

Keywords: biomarkers calprotectin cross-linked n-telopeptides
effects of palliative care on quality of life and symptom control in patients with stage iiib or stage iv non-small cell lung cancer that cannot be removed by surgery

Conditions: Lung Cancer

Summary: rationale: palliative care may be more effective than standard care in improving quality of life and symptoms in patients with lung cancer. purpose: this clinical trial is studying the effects of palliative care on quality of life and symptom control in patients with stage iiib or stage iv non-small cell lung cancer that cannot be removed by surgery.

objectives: * to compare the effects of palliative care intervention (pci) vs standard care on overall quality of life and psychological distress in patients with unresectable stage iiib or iv non-small cell lung cancer. * to compare symptom control in these patients. * to compare geriatric assessment outcomes, as measured by oars instrumental activities of daily living, mos activities of daily living, mos social activities limitation scale, hospital anxiety and depression scale scores, and karnofsky performance scale, in these patients. * to compare the effects of the pci vs standard care on resource use. * to identify subgroups of patients who benefit most from the pci in relation to sociodemographic characteristics, treatment factors, and geriatric assessment predictors at week 12. outline: patients are assigned to 1 of 2 groups. group i (usual care): patients receive standard care. group ii (palliative care intervention): patients receive an individualized interdisciplinary palliative care intervention comprising sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.

Eligibility criteria:
criteria: * diagnosis of stage iiib-iv unresectable nsclc * undergoing treatment with chemotherapy, radiation, or combined modalities * living within a 50 mile radius of the city of hope * no previous cancer within the past 5 years

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer recurrent non-small cell lung cancer
survival of bcs vs mx in asymptomatic screen-detected npbc

Conditions: Breast Cancer

Summary: we performed this study on a consecutive cohort of women with asymptomatic screen-detected npbc. the clinicopathological characteristics, 10-year relapse-free survival (rfs) and overall survival (os) were compared between bcs and mx patients among different subgroups.


Eligibility criteria:
inclusion criteria: written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures. age of at least 18 and at most 90 years. performance status (karnofsky-index) \>80%. chemotherapy is necessary before or after surgery. no clinical evidence of local recurrence or distant metastases. complete staging work-up within 3 months prior to registration. all patients must have (bilateral) mammography or breast mri, chest x-ray; other tests may be performed as clinically indicated. life expectancy of at least 2 years, disregarding the diagnosis of cancer. adequate organ function including normal red and white blood count, platelets, serum creatinine, bilirubin, and transaminases within normal range of the institution. patients must be available for and compliant to treatment and follow-up. patients registered on this trial must be treated and followed up at the participating center. exclusion criteria: known hypersensitivity reaction to the investigational compounds or incorporated substances. local recurrence and/or metastasis of breast cancer. no need of chemotherapy. pregnant or lactating patients. patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to registration. prior or concomitant secondary malignancy (except non-melanomatous skin cancer or carcinoma in situ of the uterine cervix) any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled high risk arrhythmias other serious illness or medical condition that may interfere with the understanding and giving of informed consent and the conduct of the study. concurrent treatment with other experimental drugs or any other anti-cancer therapy. males.
comparison of fatigue and recovery after stroke depending on the usual management with or without physical training

Conditions: Stroke

Summary: after a minor stroke, patients frequently report complaints such as fatigue and difficulty with certain everyday motor tasks, leading to a marked deterioration in their quality of life. the aim of this study is to show that the implementation of a personalised physical activity programme, starting 1 month after the hospitalisation for minor stroke, significantly decreases the frequency of fatigue in these patients, in comparison with usual management "in real life"..


Eligibility criteria:
inclusion criteria: * age \> 18 years * national health insurance cover * 1st minor ischaemic stroke (initial nih score ≤ 4) * satisfactory neurological recovery at discharge from hospital (modified rankin score ≤2) * patient living close to the participating centre (\<50 km) * with early post-stroke fatigue (ffs score ≥ 4 at the definitive inclusion visit (w3)) exclusion criteria: * haemorrhagic stroke * history of ischaemic or haemorrhagic stroke with clinical manifestations * history of tia * mms ≤ 24 * pre-existing dementia (defined according to dsm iv criteria) * neurosensory or orthopaedic disorders requiring permanent technical support before the stroke and making reconditioning impossible * aggravation of the neurological status after the initial hospitalisation (nih score ≥ 6) * recurrence of the cerebrovascular event or onset of an acute cardio-vascular event between the screening and definitive inclusion * pre-stroke rankin score ≥ 3 * pregnant patient * patient under guardianship
comparison of vessel-ffr versus ffr in intermediate coronary stenoses

Conditions: Coronary Artery Disease; Coronary Artery Stenoses

Summary: this is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether vffr is non-inferior to ffr in assessment of intermediate coronary stenosis in terms of the occurrence of mace during 12 months after randomization.

coronary angiography is insensitive to assess the physiologic significance of a coronary stenosis. therefore, clinical guidelines support the use of pressure-derived fractional flow reserve (ffr) to assess the hemodynamic significance of coronary stenosis. nevertheless, the penetration of ffr in clinical routine continues to be limited by its requirement for pharmacological vasodilation, prolonged procedure time and adverse systemic effects from adenosine. vessel-ffr (vffr) is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on computation of two angiographic projections. the vffr values at each point along the vessel are color-coded and superimposed on the 3d epicardial model and cut-off values of ≤0.80 identical to standard invasive ffr apply. these developments may translate towards more physiology guided intervention bearing the potential to improve clinical outcomes in patients with stable cad. the ability to derive ffr values from routinely performed coronary angiograms, without the practical drawbacks that limit invasive techniques, could have an important impact on daily clinical practice. to date no randomized outcome-based clinical trial has compared an image-based ffr methodology with standard invasive ffr in terms of subsequent clinical outcomes.

Eligibility criteria:
inclusion criteria: * age \>18 years * willing to participate and able to understand, read and sign the informed consent document before the planned procedure * eligible for coronary angiography and/or pci * coronary artery disease in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which the physiological severity of the lesion is in question (typically 40-80% diameter stenosis). * stable angina or acute coronary syndrome (non-culprit vessels only and outside of primary intervention during acute stemi or nste-acs) * participation in another interventional study exclusion criteria: * previous cabg with patent grafts to the interrogated vessel * tandem stenoses separated by more than 10 mm that require separate pressure guide wire interrogation or pci (not to be interrogated or treated as a single stenosis) * total coronary occlusions * hemodynamic instability (killip class iii-iv) * heavily calcified or tortuous vessels * terminal disease with life expectancy of less than 12 months * stemi within 48 hours of procedure * severe valvular heart disease * acs patients with difficulty in assessing which the culprit lesion is * significant contraindication to adenosine administration (e.g. asthma bronchiale) * pregnancy